Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: A case report

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Angelini, Giovanni ^a   Bonamonte, Domenico ^a   Lucchese, Alberta ^a   Favia, Gianfranco ^a   Serpico, Rosario ^b   Mittelman, Abraham ^c   Simone, Simone ^a   Sinha, Animesh A ^d   Kanduc, Darja ^a  

^a UNIVERSITY OF BARI   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; DESMOGLEIN 3; HYDROCORTISONE SODIUM SUCCINATE; PREDNISONE; PROTEIN ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CATARACT; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EPITHELIZATION; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; PEMPHIGUS VULGARIS; SKIN BIOPSY; SKIN EPITHELIUM; TREATMENT DURATION;

EID: 33750703178     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-43     Document Type: Article

References (55)

1. Holubar K: Pemphigus: a disease of man and animal. Historical and other perspectives. Int J Dermatol 1988, 27:516-520.
2. King DF, Hollubar K: History of pemphigus. Clin Dermatol 1983, 1:6-12.
3. Amagai M, Klaus-Kovtun V, Stanley JR: Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991, 67:869-877.
4. Mascaro JM Jr, Espana A, Liu Z, Ding X, Swartz SJ, Fairley JA, Diaz LA: Mechanisms of acantholysis in Pemphigus vulgaris: role of IgG valence. Cin Immunol Immunopathol 1997, 85:90-96.
5. Stanley JR: Pathophysiology and therapy of pemphigus in the 21st century. J Dermatol 2001, 28:645-646.
6. Rogul M: Pemphigus: hard to diagnose and treat. J Am Acad Dermatol 2004, 51:S21-22.
7. Harman KE, Albert S, Black MM: British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003, 149:926-937.
8. Ljubojevic S, Lipozencic J, Brenner S, Budimcic D: Pemphigus vulgaris: a review of treatment over a 19-year period. J Eur Acad Dermatol Venereol 2002, 16:599-603.
9. Toth GG, van de Meer JB, Jonkman MF: Dexamethasone pulse therapy in pemphigus. J Eur Acad Dermatol Venereol 2002, 16:607-611.
10. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH: Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003, 49:276-280.
11. Assmann T, Voss R, Ruzicka T, Megahed M: Therapy resistant pemphigus vulgaris. Combination therapy with methyiprednisolone and doxycycline. Hautarzt 2003, 54:979-981.
12. Benoit Corven C, Carvalho P, Prost C, Verret JL, Saiag P, Noblesse I, Bedane C, Chosidow O, Young P, Roujeau JC, Joly P: Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme). Ann Dermatol Venereol 2003, 130:13-15.
13. Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, Guerra R, Orazi BM: Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apheresis Sci 2003, 28:13-18.
14. Sami N, Bhol KC, Ahmed RA: Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003, 13:377-381.
15. Sami N, Qureshi A, Ruocco E, Ahmed AR: Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002, 138:1158-1162.
16. Jolles S: High-dose intravenous immunoglobulin (hdlVlg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 2002, 129:385-389.
17. Bystryn JC, Jiao, D, Natow S: Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002, 47:358-363.
18. Nguyen VT, Arredondo J, Chemyavsky Al, Pittelkow MR, Kitajima Y, Grando SA: Pemphigus vulgaris; acantholysis ameliorated by cholinergic agonists. Arch Dermatol 2004, 140:327-334.
19. Jain R, Kumar B: Immediate and delayed complications of dexamethasone cyclophosphamide pulse(DCP) therapy. J Dermatol 2003, 30:713-718.
20. Toth GG, Westerlaken BO, Eilders M, Laseur M, Jonkman MF, Uges DR: Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacother 2002, 36:1108-1109.
21. Sakallioglu EE, Acikgoz G, Keles G, Senturk N, Karagoz F: Pemphigus vulgaris and complications of systemic corticosteroid therapy: a case report. J Oral Sci 2003, 45:165-169.
22. Kanduc D: Peptimmunology: immunogenic peptides and sequence redundancy. Curr Drug Discov Technol 2005, 2:239-244.
23. Kanduc D: Defining peptide sequences: from antigenicity to immunogenicity through redundancy. Curr Pharmacogenomics 2006, 4:33-37.
24. Willers J, Lucchese A, Kanduc D, Ferrone S: Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides 1999, 20:1021-1026.
25. Natale C, Giannini T, Lucchese A, Kanduc D: Computer-assisted analysis of molecular mimicry between HPV16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000, 78:580-585.
26. Mittelman A, Lucchese A, Sinha AA, Kanduc D: Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome. Int J Cancer 2002, 98:741-747.
27. Dummer R, Mittelman A, Fanizzi FP, Lucchese G, Willers J, Kanduc D: Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer 2004, 111:720-726.
28. Kanduc D, Fanizzi FP, Lucchese G, Stevanovic S, Sinha AA, Mittelman A: NMR probing of in silico identification of anti-HPV16 E7 mAb linear peptide epitope. Peptides 2004, 25:243-250.
29. Mittelman A, Tiwari R, Lucchese G, Willers J, Dummer R, Kanduc D: Identification of Monoclonal Anti-HMW-MAA Antibody Linear Peptide Epitope by Proteomic Database Mining. J Invest Dermat 2004, 123:670-675.
30. Willers J, Lucchese A, Mittelman A, Dummer R, Kanduc D: Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis. Exp Dermatol 2005, 14:543-50.
31. Lucchese A, Willers J, Mittelman A, Kanduc D, Dummer R: Proteomic scan for tyrosinase peptide antigenic pattern in vitiligo and melanoma. Role of sequence similarity and HLA-DRI affinity. J Immunol 2005, 175:7009-7020.
32. Lucchese A, Mittelman A, Lin MS, Kanduc D, Sinha AA. Epitope definition by proteomic similarity analysis: identification of the linear determinant of the anti-Dsg3 MAb 5H10. J Transl Med 2004, 2:43.
33. Angelini G, Bonamonte D, Lin MS, Lucchese A, Mittelman A, Serpico R, Simone S, Sinha AA, Kanduc D: Characterization of polyclonal antibodies raised against a linear peptide determinant of desmoglein-3. J Exp Ther Oncol 2005, 5:1-7.
34. Lucchese A, Mittelman A, Tessitore L, Serpico R, Sinha AA, Kanduc D: Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous. J Transl Med 2006, 4:37.
35. Salato VK, Foegen MK, Lazarova Z, Fairley JA, Lin MS: The role of intra-molecular epitope spreading in the development and transition of pemphigus vulgaris. J Invest Dermatol 2004, 122:A6-Abstr 031.
36. Krause I, Blank M, Shoenfeld Y: Peptide immunotherapy in autoimmune diseases. Drug News Perspect 2000, 13:78-84.
37. Tarzi M, Larché M: Peptide immunotherapy for allergic disease. Expert Opin Biol Ther 2003, 3:617-626.
38. Singh RR, Ebling FM, Sercarz EE, Hahn BH: Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995, 96:2990-2996.
39. Jouanne C, Avrameas S, Payelle Brogard B: A peptide derived from a polyreactive monoclonal anti-DNA natural antibody can modulate lupus development in (NZBxNZW) FI mice. Immunology 1999, 96:333-339.
40. Sharabi A, Zinger H, Zborowsky M, Sthoeger ZM, Mozes E: A peptide based on the complementarity-determining region I of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci USA 2006, 103:8810-8815.
41. Villen J, Oliveira EdE, Nunez JI, Molina N, Sobrino F, Andreu D: Towards a multi-site synthetic vaccine to foot-and-mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals. Vaccine 2004, 22:3523-3529.
42. Jackson DJ, Elson CJ, Kumpel BM: Reduction of human anti-tetanus toxoid antibody in hu-PBL-SCID mice by immunodominant peptides of tetanus toxoid. Clin Exp Immunol 2004, 137:245-252.
43. Haselden BM, Kay AB, Larché M: Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000, 122:229-237.
44. von Garnier C, Astori M, Kettner A, Dufour N, Heusser C, Corradin G, Spertini F: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000, 30:1638-1645.
45. Wauben MH: Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 2000, 20:451-469.
46. Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT: De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-I glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 2004, 279:24141-24151.
47. Gorse GJ, Keefer MC, Belshe RB, Matthews TJ, Forrest BD, Hsieh RH, Koff WC, Hanson CV, Dolin R, Weinhold KJ, Frey SE, Ketter N, Fast PE: A dose-ranging study of a prototype synthetic HIV-IMN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996, 173:330-339.
48. Langhans B, Braunschweiger I, Schweitzer S, Sauerbruch T, Spengler U: Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides. Vaccine 2004, 22:1441-1447.
49. Schenk D: Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002, 3:824-828.
50. Miller SD, Katz-Levy Y, Neville KL, Vanderlugt CL: Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv Virus Res 2001, 56:199-217.
51. Tian J, Olcott AP, Kaufman DL: Antigen-based immunotherapy drives the precocious development of autoimmunity. J Immunol 2002, 169:6564-6569.
52. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH: Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J Immunol 2000, 164:580-588.
53. Wucherpfennig KW, Yu B, Bhol K, Monos DS, Argyris E, Karr RW, Ahmed AR, Strominger JL: Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natl Acad Sci USA 1995, 92:11935-11939.
54. Tong JC, Bramson J, Kanduc D, Chow S, Sinha AA, Ranganathan S: Modeling the bound conformation of Pemphigus Vulgaris-associated peptides to MHC Class II DR and DQ Alleles. Immunome Res 2006, 2:1.
55. Veldman CM, Gebhard KL, Uter W, Wassmuth R, Grotzinger J, Schultz E, Hertl M: T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol 2004, 172:3883-3892.